Insulet Co. (NASDAQ:PODD) Shares Sold by DAFNA Capital Management LLC

DAFNA Capital Management LLC lessened its holdings in shares of Insulet Co. (NASDAQ:PODD) by 22.0% in the fourth quarter, Holdings Channel.com reports. The firm owned 12,400 shares of the medical instruments supplier’s stock after selling 3,500 shares during the period. Insulet comprises 0.8% of DAFNA Capital Management LLC’s portfolio, making the stock its 29th largest holding. DAFNA Capital Management LLC’s holdings in Insulet were worth $3,237,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of PODD. SBI Securities Co. Ltd. bought a new stake in shares of Insulet in the fourth quarter worth $36,000. Itau Unibanco Holding S.A. acquired a new stake in Insulet in the fourth quarter worth approximately $42,000. SRS Capital Advisors Inc. grew its holdings in Insulet by 43.1% during the fourth quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier’s stock worth $49,000 after acquiring an additional 56 shares during the period. Friedenthal Financial purchased a new position in Insulet in the 4th quarter worth about $57,000. Finally, Assetmark Inc. boosted its stake in Insulet by 1,447.1% in the 4th quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier’s stock worth $69,000 after purchasing an additional 246 shares during the period.

Insider Transactions at Insulet

In other Insulet news, Director Wayne A.I. Frederick sold 1,825 shares of the business’s stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total transaction of $501,875.00. Following the transaction, the director now owns 3,231 shares of the company’s stock, valued at $888,525. The trade was a 36.10 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.47% of the stock is owned by company insiders.

Insulet Price Performance

NASDAQ:PODD opened at $264.02 on Thursday. Insulet Co. has a 52-week low of $160.19 and a 52-week high of $289.46. The company has a market cap of $18.58 billion, a P/E ratio of 45.60, a P/E/G ratio of 3.62 and a beta of 1.26. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The stock’s 50-day simple moving average is $256.95 and its 200 day simple moving average is $262.85.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.00 by $0.15. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The company had revenue of $597.50 million for the quarter, compared to analysts’ expectations of $582.02 million. As a group, sell-side analysts forecast that Insulet Co. will post 3.92 EPS for the current fiscal year.

Analyst Ratings Changes

PODD has been the topic of several research analyst reports. Wells Fargo & Company set a $322.00 price target on shares of Insulet in a report on Monday, April 28th. Citigroup increased their price target on shares of Insulet from $310.00 to $355.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Royal Bank of Canada assumed coverage on shares of Insulet in a report on Thursday, March 6th. They issued an “outperform” rating and a $340.00 price objective for the company. Piper Sandler boosted their price target on Insulet from $285.00 to $310.00 and gave the stock an “overweight” rating in a research report on Friday, February 21st. Finally, Barclays lifted their price target on Insulet from $234.00 to $266.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 30th. Five analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat, Insulet currently has a consensus rating of “Moderate Buy” and a consensus price target of $299.81.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.